Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 38OTHER 24NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Has results × daratumumab × Clear all
NCT03710603 2026-02-10

Perseus

European Myeloma Network B.V.

Phase 3 Active not recruiting
709 enrolled 17 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Intergroupe Francophone du Myelome

Phase 3 Completed
1,085 enrolled 22 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡